Table 3.

Percentage of patients who achieved total field clearance of actinic keratosis at 3 and 12 months

Treatment	3 months	12 months
5‐FU	96% 8 , 84% 40 , 43% 43 , 38% 42 ; 62.5% 44 ,52% 58 ,49 17 ,43–96% 1	33% 8 33% 17 ,28%–62% 1 ,22% 42
Imiquimod	85% 8 , 68.9% 59 , 57.1% 60 , 55% 49 , 53.7% 50 , 50% 61 , 48.3% 45 , 45.1% 47 , 35.6% 48 , 35.6% 56 , 30.2% 46 , 24% 40 ; 84% 17 ,70% 58 ,50% 37 ,37.1% 9 ,26.8–55% 1	73% 8 ; 32.7% 50
Diclofenac	58% 57 , 47% 62 ; 31.3% 9	24% 63
Ingenol mebutate	42.4% 37 , 42.2% 27 ; 42% 1 , 33.1% 9	18.5% 1 ; 22.8% 27
ALA‐PDT	69% 64 , 59.2% 54 , 59% 65 ; 59–91% 1 ,58% 9 ,	49–75.5% 1 ; 34.8% 37 , 65
Cryotherapy (only visible lesions treated)	Not available	4% 8 , 3.3% 46

Primary study results (direct data) are in bold; review study estimates are in italics; and calculated percentages are underlined.